John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.
Videos
Nicolas Girard, MD, PhD, discusses the rationale of targeting PD-L1 and LAG-3 in NSCLC in the RELATIVITY-104 study.
Ticiana Leal, MD, discusses how in cases of extensive stage small cell lung cancer (ES-SCLC) that progress within 6 months of platinum-based chemotherapy, treatment options such as tarlatamab, lurbinectedin, topotecan, and irinotecan should be considered, alongside the potential to extend chemoimmunotherapy cycles. She also addresses the impact of National Comprehensive Cancer Network (NCCN) guidelines and the consideration of prophylactic cranial irradiation (PCI) despite negative brain imaging results.
Panelists discuss how NICHE-2 trial updates offer valuable insights into the role of minimal residual disease assessment in guiding neoadjuvant immunotherapy for colorectal cancer patients.
Panelists discuss how updates from the POD1UM-303/InterAACT2 trial presented at European Society for Medical Oncology Congress (ESMO) 2024 shed light on retifanlimab’s potential role in advancing treatment options for anal cancer patients.
Panelists discuss how KEYNOTE-811's study design and key findings presented at the European Society for Medical Oncology (ESMO) Congress 2024 demonstrate the potential impact of pembrolizumab plus trastuzumab and chemotherapy in HER2-positive gastric cancer treatment.
Panelists discuss how LEAP-012 trial results show promising progression-free survival, while anticipating further data on overall survival outcomes.
Amy Selly, CNP, AOCNP, discusses how physicians can support their patients' survivorship journeys.
Amy Selly, CNP, AOCNP, discusses the challenges facing cancer survivors from underserved populations.
Amy Selly, CNP, AOCNP, discusses the role support plays in the cancer survivor experience.
Amy Selly, CNP, AOCNP, discusses the varying challenges facing cancer patients and survivors.
Amy Selly, CNP, AOCNP, discusses how cancer as a chronic illness impacts definitions of survivorship.
Amy Selly, CNP, AOCNP, discusses the different definitions of cancer survivorship.
Angeles Alvarez Secord, MD, MHSc, discusses key takeaways from the PICCOLO trial.
Erika P. Hamilton, MD, discusses the patient population with breast cancer enrolled in the TROPION-PanTumor01 trial in relation to the efficacy of datopotamab deruxtecan.
David Braun, MD, PhD, discusses how biomarkers are evolving for the treatment of renal cell carcinoma.
Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from the phase 3 CLEAR study in advanced renal cell carcinoma (RCC).
Ticiana Leal, MD, discusses how recently approved targeted therapies for small cell lung cancer (SCLC) significantly enhance survival outcomes and reshape treatment strategies for both limited and extensive stages of the disease.
Byoung Chul Cho, MD, PhD, discusses the implications of the CHRYSALIS-2 study of amivantamab and lazertinib.
Panelists discuss how final thoughts emphasize the importance of ongoing research, collaborative care, and adapting treatment strategies to improve patient outcomes in the evolving therapy landscape.
Panelists discuss how surgical perspectives on durvalumab emphasize its role in enhancing patient outcomes, informing surgical decision-making, and integrating immunotherapy into comprehensive treatment plans.
Panelists discuss how considerations for treatment approach encompass patient-specific factors, treatment modalities, and the integration of emerging therapies to optimize outcomes in clinical practice.
Panelists discuss how the results and outcomes of the AEGEAN trial reveal significant findings regarding the treatment’s effectiveness and safety, shaping future approaches in patient care and management.
Panelists discuss how the importance of AEGEAN approval lies in its potential to enhance patient treatment options, paving the way for improved outcomes and informing clinical practice in the field.
Panelists discuss how the AEGEAN trial provides critical insights into the efficacy and safety of new therapeutic approaches, highlighting its design, key findings, and implications for future treatment strategies.
Joshua K. Sabari, MD, discusses how tarlatamab, a BiTE, demonstrates a unique mechanism of action by targeting DLL3, which is aberrantly expressed in 85% to 94% of SCLC cells, thereby directing T cells to these cancer cells independently of MHC class I and promoting T-cell–mediated tumor lysis and regression.
Panelists discuss how specific disease characteristics, such as tumor burden, metastatic sites, and risk stratification, most strongly influence their decision-making process when choosing between immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI plus TKI) regimens and dual immune checkpoint inhibitor (ICI plus ICI) combinations for treating metastatic renal cell carcinoma.
Yoshiaki Nakamura, MD, PhD, discusses how the COSMOS-CRC-01 study was designed to evaluate the efficacy of ctDNA analysis for MRD detection, outlining the rationale for patient enrollment, the timing of plasma sample collection, and the implications for monitoring disease post surgery and during adjuvant chemotherapy.
Panelists discuss how they approach selecting among various immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combinations for first-line treatment of metastatic renal cell carcinoma, considering key factors that influence their decision-making process and drawing insights from recent clinical trials such as CheckMate 9ER, KEYNOTE-426, and CLEAR.
Joshua K. Sabari, MD, discusses how, despite negative results from serial brain MRIs, the consideration of PCI in patients with ES-SCLC depends on individual risk factors, including the likelihood of brain metastases and the overall treatment strategy aimed at improving outcomes.